LLY

949.03

+1.48%↑

NVO

142.18

+1.62%↑

UNH

511.99

+1.33%↑

JNJ

149.82

+0.04%↑

MRK

127.38

-1.16%↓

LLY

949.03

+1.48%↑

NVO

142.18

+1.62%↑

UNH

511.99

+1.33%↑

JNJ

149.82

+0.04%↑

MRK

127.38

-1.16%↓

LLY

949.03

+1.48%↑

NVO

142.18

+1.62%↑

UNH

511.99

+1.33%↑

JNJ

149.82

+0.04%↑

MRK

127.38

-1.16%↓

LLY

949.03

+1.48%↑

NVO

142.18

+1.62%↑

UNH

511.99

+1.33%↑

JNJ

149.82

+0.04%↑

MRK

127.38

-1.16%↓

LLY

949.03

+1.48%↑

NVO

142.18

+1.62%↑

UNH

511.99

+1.33%↑

JNJ

149.82

+0.04%↑

MRK

127.38

-1.16%↓

Search

BioMarin Pharmaceutical Inc

Suletud

Sektor Tervishoid

85.07 1.29

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

84.8

Max

85.66

Põhinäitajad

By Trading Economics

Sissetulek

68M

89M

Müük

2.8M

649M

P/E

Sektori keskmine

125.462

23.904

Aktsiakasum

0.71

Kasumimarginaal

13.661

Töötajad

3,401

EBITDA

81M

136M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+27.41 upside

Turustatistika

By TradingEconomics

Turukapital

-330M

15B

Eelmine avamishind

83.78

Eelmine sulgemishind

85.07

Uudiste sentiment

By Acuity

50%

50%

117 / 369 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bullish Evidence

BioMarin Pharmaceutical Inc Graafik

Seotud uudised

10. juuni 2024, 17:41 UTC

Suurimad hinnamuutused turgudel

Texas Pacific Land, Altair Engineering Hit 52-Week Highs on S&P MidCap 400 Inclusion

Võrdlus sarnastega

Hinnamuutus

BioMarin Pharmaceutical Inc Prognoos

Hinnasiht

By TipRanks

27.41% tõus

12 kuu keskmine prognoos

Keskmine 108.32 USD  27.41%

Kõrge 140 USD

Madal 72 USD

Põhineb 21 Wall Streeti analüütiku instrumendi BioMarin Pharmaceutical Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

21 ratings

14

Osta

7

Hoia

0

Müü

Tehniline skoor

By Trading Central

82.15 / N/AToetus ja vastupanu

Lühikene perspektiiv

Very Strong Bullish Evidence

Keskpikk perspektiiv

Weak Bearish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

117 / 369 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest BioMarin Pharmaceutical Inc

BioMarin Pharmaceutical Inc. is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company's therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A). The Company is conducting clinical trials on various product candidates for the treatment of various diseases. Its clinical product candidates include Brineura, pegvaliase, vosoritide, BMN 270 and BMN 250.